# name
Enzymatic replacement therapy for lysosomal storage disorders: Drug evaluations review in Spain

# metadata.dc.description.abstract[].value
In the European Union companies only need to demonstrate that the risk-benefit balance of the new drug is favourable to obtain the authorization to sell new drugs. Hence a comparison with available treatments, a cost-effectiveness analysis and the place in the therapy of the new drug are not required. Therefore, it is necessary to carry out these analyses in an additional study. In Spain there is no national government agency, which conducts a centralized evaluation and makes decisions on funding and are the Pharmacy and Therapeutics committees that take mandatory decisions for the entire region.

# metadata.dc.relation.ispartof[].value
Health Policy and Technology, 2019, vol. 8, num. 1, p. 14-23

# metadata.dc.rights[].value
cc-by-nc-nd (c) Fellowship of Postgraduate Medicine, 2019

# metadata.dc.source[].value
Articles publicats en revistes (Economia)

# metadata.dc.title[].value
Enzymatic replacement therapy for lysosomal storage disorders: Drug evaluations review in Spain